A pioneering research centre which could improve the way diabetes is treated in the future has opened in Oxford. The aim of the Novo Nordisk Research Centre Oxford (NNRCO) is to pursue innovative medicines to help treat and prevent type 2 diabetes while also helping to train the next generation of researchers.
The building is a collaborative partnership between the University of Oxford and the pharmaceutical giant Novo Nordisk, which has invested £115m into the project for the next 10 years.
Business Secretary Greg Clark said: “This centre has the potential to transform the way diabetes is treated in the future and improve the lives of people around the world. Our universities and research institutes are world beating and this international investment in the UK is a vote of confidence in both the talent we have and the quality of research and products our scientists develop.